Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen X Chen

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Methods in Molecular Medicine|November 1, 2002
Clinical development of antisense oligonucleotides as anti-cancer therapeuticsHelen X Chen
The Oncologist|June 5, 2004
Expanding the clinical development of bevacizumabHelen X Chen
Chinese Journal of Cancer|April 23, 2013
IGF-1R as an anti-cancer target--trials and tribulationsHelen X Chen, Elad Sharon
Chinese Journal of Cancer|December 6, 2014
Cancer immunotherapyLi Yan, Helen X Chen
Nature Reviews. Drug Discovery|August 3, 2006
Strategies for optimizing combinations of molecularly targeted anticancer agentsJanet E Dancey, Helen X Chen
JAMA Oncology|July 17, 2015
Genomic Profiling: Building a Continuum From Knowledge to CareHelen X Chen, Jeffrey S Abrams
Nature Reviews. Clinical Oncology|July 8, 2009
Adverse effects of anticancer agents that target the VEGF pathwayHelen X Chen, Jessica N Cleck
Chinese Journal of Cancer|September 6, 2014
Immune checkpoint inhibitors in clinical trialsElad Sharon, Howard Streicher, Priscila Goncalves, et al.
Current Problems in Cancer|January 20, 2010
Epidermal growth factor receptor inhibitors: current status and future directionsHelen X Chen, Jessica N Cleck, Rochelle Coelho, et al.
Current Problems in Cancer|January 20, 2010
ForewordHelen X Chen, Jessica N Cleck, Rochelle Coelho, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Methods in Molecular Medicine|November 1, 2002
Clinical development of antisense oligonucleotides as anti-cancer therapeuticsHelen X Chen
The Oncologist|June 5, 2004
Expanding the clinical development of bevacizumabHelen X Chen
Chinese Journal of Cancer|April 23, 2013
IGF-1R as an anti-cancer target--trials and tribulationsHelen X Chen, Elad Sharon
Chinese Journal of Cancer|December 6, 2014
Cancer immunotherapyLi Yan, Helen X Chen
Nature Reviews. Drug Discovery|August 3, 2006
Strategies for optimizing combinations of molecularly targeted anticancer agentsJanet E Dancey, Helen X Chen
JAMA Oncology|July 17, 2015
Genomic Profiling: Building a Continuum From Knowledge to CareHelen X Chen, Jeffrey S Abrams
Nature Reviews. Clinical Oncology|July 8, 2009
Adverse effects of anticancer agents that target the VEGF pathwayHelen X Chen, Jessica N Cleck
Chinese Journal of Cancer|September 6, 2014
Immune checkpoint inhibitors in clinical trialsElad Sharon, Howard Streicher, Priscila Goncalves, et al.
Current Problems in Cancer|January 20, 2010
Epidermal growth factor receptor inhibitors: current status and future directionsHelen X Chen, Jessica N Cleck, Rochelle Coelho, et al.
Current Problems in Cancer|January 20, 2010
ForewordHelen X Chen, Jessica N Cleck, Rochelle Coelho, et al.
Pageof 9